Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase II Results of ECOG-ACRIN EA9152: A multicenter study of liposomal vincristine (L-VCR) or vincristine sulfate (VCR) and venetoclax (VEN) in relapsed or refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL)

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJonathan WebsterMLMark R. Litzow

Discussion

Loading...

Member takes

Overview

Multicenter analysis shows limited complete response rates and median survival outcomes in relapsed lymphoblastic lymphoma, suggesting better strategies are needed.

Key Points

  • The combination of venetoclax and vincristine demonstrated limited efficacy with no complete responses seen in B-cell ALL cohorts.
  • Overall survival for B-cell patients was only 4.3 months, highlighting the poor outcomes in this high-risk population.
  • Observational analysis of treatment included venetoclax with both liposomal and standard vincristine formulations.
  • The safety profile was deemed acceptable, although treatment-related adverse events were common, with serious instances reported.

Cite This Study

Webster et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236dea8https://doi.org/10.1182/blood-2025-1577
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial2025 · 2 citations
  2. 2Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for acute lymphoblastic leukemia following allogeneic stem cell transplantation2025
  3. 3Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis2025
  4. 4Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia2025
  5. 5Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure2025